Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Chronic lymphocytic leukemia (CLL) * B-cell small lymphocytic leukemia (SLL) * Any marginal zone lymphoma * Grade 1-3A follicular lymphoma * Waldenstrom's macroglobulinemia * Mantle cell lymphoma * No transformed indolent lymphoma * Assessable disease (phase I) * Measurable disease (phase I and II), defined as ≥ one lesion that can be accurately measured in ≥ 1 dimension as ≥ 2 cm by conventional techniques OR ≥ 1 cm by spiral CT scan * Lymph nodes measuring ≤ 1 cm in the short axis are considered normal * Relapsed or refractory disease * Must have received at least 1 prior therapeutic regimen but no more than 3 prior conventional cytotoxic therapy regimens * No known brain metastases or meningeal disease PATIENT CHARACTERISTICS: * Karnofsky performance status \> 50% * Absolute neutrophil count \> 1,000/mcl (more than 500/mcl if known lymphomatous involvement) * Platelet count ≥ 50,000/mcl * Total bilirubin \< 1.5 times upper limit of normal (ULN) (less than 5 mg/dL if known history of Gilbert's disease) * AST and ALT ≤ 2.5 times ULN (4 times ULN if liver involvement) * Creatinine \< 1.5 times ULN OR creatinine clearance \> 50 mL/min * Patients may have febrile episodes up to 38.5ºC without evidence of active infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No New York Heart Association class III or IV …